These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 24344323

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
    Pratt CM, Roy D, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Retyk E, Drenning DH, Atrial Arrhythmia Conversion Trial (ACT-III) Investigators.
    Am J Cardiol; 2010 Nov 01; 106(9):1277-83. PubMed ID: 21029824
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Vernakalant--a new drug for pharmacological conversion of atrial fibrillation].
    Hinneburg I.
    Med Monatsschr Pharm; 2011 May 01; 34(5):154-8. PubMed ID: 21644373
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
    Duggan ST, Scott LJ.
    Drugs; 2011 Jan 22; 71(2):237-52. PubMed ID: 21275448
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Vernakalant: pharmacology electrophysiology, safety and efficacy.
    Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Stevenson R, Gonzalez MD.
    Drugs Today (Barc); 2008 May 22; 44(5):325-9. PubMed ID: 18548135
    [Abstract] [Full Text] [Related]

  • 14. [Clinical case of the month. Atrial flutter with rapid ventricular response (1:1 atrioventricular conduction) caused by flecaïnide].
    Robinet S, Melon R, Piérard L.
    Rev Med Liege; 2007 Dec 22; 62(12):701-3. PubMed ID: 18286943
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity.
    Blomström-Lundqvist C, Blomström P.
    Expert Opin Drug Saf; 2012 Jul 22; 11(4):671-9. PubMed ID: 22632377
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of intravenous vernakalant for the rapid conversion of recent-onset atrial fibrillation: A meta-analysis.
    Akel T, Lafferty J.
    Ann Noninvasive Electrocardiol; 2018 May 22; 23(3):e12508. PubMed ID: 29105209
    [Abstract] [Full Text] [Related]

  • 18. Vernakalant: additional evidence for safety and efficacy for new onset atrial fibrillation.
    Lindsay BD.
    J Am Coll Cardiol; 2011 Jan 18; 57(3):322-3. PubMed ID: 21232670
    [No Abstract] [Full Text] [Related]

  • 19. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.
    Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ, Atrial Arrhythmia Conversion Trial Investigators.
    Circulation; 2008 Mar 25; 117(12):1518-25. PubMed ID: 18332267
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.